Every fact traced to its source, and checked against it. Explore the companies, facts, and conclusions behind the news.
Conclusions our AI is drawing from the traced facts — read them as interpretation, each grounded in the data and the entities it names.
October 2026 is dense with clinical and regulatory news. Phase 3 trials hit primary endpoints (ALOFT-IPF, RESTORE-3), long-term data came out (MIUDELLA at 6 years, QUILT-3.032), and the FDA accepted Roche's vamikibart BLA. Scholar Rock resubmitted its apitegromab MAA to the EMA. The next catalysts are ESMO 2026 (Oct 23) and the Nov 14 FDA PDUFA date for ivonescimab, followed by Maritime-1 primary completion in January 2027. The speculative QAIAx items (QIII pilot, microcities patent) are a weak, tangential thread with little financial substance.
Enterprise software vendors (ServiceNow, SAP, Palantir, Zeta, Meta) are racing to launch autonomous-agent platforms. The emphasis is shifting to governance, control and data sovereignty, especially for regulated sectors like banking, as seen in Customers Bank's AI-native banking tie-up with Palantir. Venture investors such as Norwest see opportunity to disrupt finance and ERP incumbents (NetSuite, Sage) through CFO-led buying. Consolidation and talent moves, including Tiny's purchase of Oso Cloud (an authorization vendor serving fintech) and MongoDB's CEO leaving for Meta, signal intensifying competition for the enterprise AI stack.
Mid-October 2026 brought a cluster of CEO and board changes (Fox Factory, Bausch + Lomb, Mattel, Brown-Forman, Odyssey) alongside structural moves such as spin-outs, divestitures, a reverse split and a de-SPAC-style combination (XCF/DevvStream). Companies are using the Q3 earnings window to reset leadership, simplify portfolios and tighten governance. Many of these moves follow weak results (Fox Factory's preliminary Q3 miss) or are driven by activist and shareholder engagement (Stride board additions).
In mid-October 2026, tech executives announced a wave of products that move AI from experimentation to agentic deployment. They span on-device compute (NVIDIA RTX Spark laptops, ASUS, Adobe, Microsoft's 'hybrid intelligence'), enterprise governance (ServiceNow's AI Passport and Control Tower), AI embedded in financial and customer workflows (Intuit, Parloa/TELUS, Brand Concierge), and open data-center hardware (Cisco/NVIDIA 400G optics, Marvell). A countercurrent of safety and ownership concerns runs alongside it: OpenAI's safety-transparency lead resigned, and Mark Chen forecast open-source models with frontier-class capabilities within 6 to 12 months.
In early to mid October 2026, sell-side and independent analysts (Zambonin, Fiorillo, Canady, Zaccardi) turned more bullish on Palantir. They cite customer expansion, net dollar retention, and complementary customer-built AI apps. Palantir also announced a run of ecosystem partnerships in a few days: Customers Bank (AI-native banking), Ondas (Regna AI) and Armada (sovereign AI infrastructure). Over the same period J.P. Morgan's Seth Seifman described weak A&D sentiment, downgraded Leidos and flagged midterm-election and FY2027 budget uncertainty.
Finance chiefs are changing hands (Rivian to GE Vernova, PJT Partners, Penguin Solutions, Fox Factory's interim CEO) while companies run cost programs and restructurings: NIKE's Pace model, Fox Factory's profit optimization, merger synergies at a bank, Marucci divestiture guidance, and debt refinancing. In parallel, AI is moving into the finance function, with PwC and SAP extending their collaboration, SAP showing its Autonomous Enterprise, and Morgan Foods preparing for agentic adoption. Regulation (the Durbin Amendment at Origin Bancorp from mid-2027, FDA PDUFA dates) and a dense run of Q3 earnings and Investor Days add near-term catalysts.
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Samsung will likely announce a unified smart home AI platform or hub within 2-3 months that connects these disparate AI-enabled products
Sustained AI feature expansion across Samsung ecosystem in Q1-Q2 2026, with likely follow-up announcements for mobile devices and additional appliances
NVIDIA GPU acceleration is becoming the dominant infrastructure for AI chip design and EDA workflows, creating a self-reinforcing ecosystem where AI chips are designed using AI-accelerated tools
88% confidence · untestedData center infrastructure investments are shifting from traditional cloud providers to AI-specific facilities, with hyperscalers willing to commit $20B+ multi-year contracts for AI-optimized data center capacity, creating opportunities for specialized infrastructure developers
88% confidence · untestedLLM sycophancy is primarily caused by reinforcement learning from human feedback (RLHF) optimization for user approval rather than truthfulness, creating a systematic bias that degrades model reliability in extended conversations
85% confidence · untestedHyperscaler AI infrastructure investments exceeding $200B combined will drive semiconductor demand and AI chip production capacity expansion in 2026
85% confidence · untestedAI safety concerns are escalating as models gain access to classified and sensitive data, creating new security vulnerabilities and ethical challenges around training data governance
85% confidence · untested5 Interesting Startup Deals You May Have Missed: A Credit Card Backed By Mineral Rights, Flying Ferries, And A Foundation AI Model For Plants
“Crunchbase News - Funding Ma Title: 5 Interesting Startup Deals You May Have Missed: A Credit Card Backed By Mineral Rights, Flying Ferries, And A Foundation AI Model For Plants Date: 2026-04-07 11:00 Source: https://news.crunchbase.com/venture/interesting-startup-deals-mineral-rights-flying-ferry-ai-clean-tech/ <p><em…”
BYDFi rozszerza swoją obecność w Europie, sponsorując targi Next Block Expo 2026 w Warszawie
“BYDFi rozszerza swoją obecność w Europie, sponsorując targi Next Block Expo 2026 w Warszawie WARSZAWA, Polska, March 26, 2026 (GLOBE NEWSWIRE) -- Globalna platforma handlu kryptowalutami BYDFi wspiera jako sponsor targi Next Block Expo 2026, które odbywają się w dniach 24–25 marca w Warszawie…”
Stocks Rally on a Push for Diplomacy to End US-Iran War
“Stocks Rally on a Push for Diplomacy to End US-Iran War The S&P 500 Index ($SPX) (SPY) on Tuesday closed up +1.18%, the Dow Jones Industrial Average ($DOWI) (DIA) closed up +0.66%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed up +1.81%…”
NTT Scientists Contribute Fifteen Research Papers to NeurIPS 2025
“NTT Scientists Contribute Fifteen Research Papers to NeurIPS 2025 NTT Research, NTT, Inc. and NTT DATA showcase foundational theory, system-level advances and enterprise-grade innovations across five major themes at premier AI conference News Highlights: NTT Research, NTT, Inc…”
Libtayo® (cemiplimab) Recommended for EU Approval by the CHMP for Updated Dosing Regimen Across All Approved Cancer Types
“Libtayo® (cemiplimab) Recommended for EU Approval by the CHMP for Updated Dosing Regimen Across All Approved Cancer Types Regeneron Pharmaceuticals, Inc…”
Top oil and energy stocks to watch as crude swings wildly amid Iran war
“Top oil and energy stocks to watch as crude swings wildly amid Iran war The war has heightened fears of disruption to global oil (BZ=F, CL=F) supplies, particularly around the Strait of Hormuz, widely regarded as the world’s most important oil chokepoint…”
Two different margin values (16% vs 18%) are recorded for the same entity (Shopify Inc.) at the identical timestamp (2026-08-05 00:00:00). With no distinguishing context (same period designation, no qualifier for margin type), these represent conflicting data about the same fact.
Fact B (Q1 2026) and Fact A (Q2 2026) are recorded as observed on the same date: 2026-03-29. This is temporally impossible, since Q2 2026 (April–June) has not yet occurred as of 2026-03-29 (mid-Q1). Financial results for a future period cannot be observed before that period ends. Additionally, 3.7 USD is implausibly low as a cash position for Qualcomm Incorporated, suggesting a data entry error in Fact B.
Both facts measure EPS for Citigroup with identical observation dates (2025-12-31). FACT A explicitly specifies FY 2025 annual EPS at 6.99 USD/share, while FACT B reports 1.65 USD with an unspecified fiscal period (N/A). The values differ by a factor of ~4.2x, which is too large to explain by rounding, methodology, or data quality variance. While FACT B's 'N/A' fiscal period introduces ambiguity about whether it represents the same annual period, both observations are timestamped identically and purport to measure the same metric on the same date. If both represent FY 2025 annual EPS, this is a direct value conflict. If FACT B represents a different period (e.g., quarterly, TTM, or interim), the ambiguous labeling still constitutes a data quality issue that obscures the reconciliation.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
Both facts measure the same attribute (cash) for the same entity (Tesla Inc.) at the same point in time (2025-12-31). Although labeled with different fiscal period categories (FY 2025 vs Q4 2025), both periods end on the same date, making them equivalent time snapshots. The values differ drastically: $16.513 billion vs $44.06 USD. Since Q4 2025 is the final quarter of FY 2025, both should report identical cash balances at period-end. A 375 million-fold magnitude difference indicates a real contradiction, likely caused by a data quality issue (unit error, miscategorization, or source error in FACT B).
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Every fact is traceable to the document it came from — see how we source every claim.
Analysts turned more bullish on Palantir in mid-October 2026 while J.P. Morgan's lead defence analyst downgraded Leidos and warned of a weak sector. The dossier holds little European regulatory material, so we say so, and set out what was said, by whom, and how reliable the sources are.
SAP, Zeta and others are launching agent platforms, while the smaller deals show money flowing to the layers that keep agents in check. Our dossier has little on EU regulation, so we say so. It does contain a clear argument that rules must be enforced by the system, and a warning not to trust AI with finance arithmetic.
A CHMP opinion for Trodelvy, a German-first Optune Pax launch and real-world German data on mogamulizumab give Europe its own oncology story in a US-heavy October. Summit's SEC-verified accounts show how costly the biggest catalyst, ivonescimab, is to reach. Some sources here fared poorly in our reliability checks.
A French networking tie-up and a Dutch equipment maker sit at the European edge of an AI-driven memory and interconnect squeeze. SEC-verified Micron filings show how fast its spending has grown. We separate the checked figures from analyst opinion and flag where the sources are weak.
Three oncology storylines are converging: new-modality drugs nearing decisions, AI-built biologics, and a care-delivery buyout. For European readers the clearest signals are an EMA committee opinion and a Swiss-based device maker's EU launch. Summit's checked SEC filings show what a late-stage bet costs. Source reliability is flagged throughout.
Verified SEC data show Micron's annual capital spending nearly doubled to $15.9bn in fiscal 2025. Meanwhile Nvidia is locking down memory supply, and France's Kalray and Bull are pursuing AI networking. Much of the supporting reporting is only partly reliable, and we show where.
The EU regulator has backed a new first-line breast cancer combination and Novocure has won a CE Mark, while US decisions on ivonescimab and a personalised mRNA vaccine arrive by 14 November. Merck's SEC-verified numbers show cash moving sharply and capex falling. Our sources vary widely in reliability, and we say where.
A European regulator backed a new first-line breast cancer combination, and a Swiss-based device maker reported record revenue while opening a German launch. Behind both sits a pipeline built on AI, mRNA and antibody-drug combinations. We separate what is verified from what is still a claim.
SEC-filed figures show Micron's capital spending almost doubled in a year and its cash pile reached $25 billion. Analysts are bullish on AI-infrastructure names but flag stretched valuations. The dossier holds little EU regulatory material, and we say so.
SEC-filed figures show Micron's capital spending nearly doubled in a year, while Europe's visible role is ASML's rally and a Kalray–Bull networking pact. Analysts' 33% to 49% upside calls come from a source whose claims held up only 22% of the time in our checks.
A survey reported by MIT Technology Review finds every respondent plans to use agentic AI within two years, yet AI reaches only about 45% of company data and only about half trust their agents. Deals from Manulife, Box and Nvidia show where the money is going. That source scores poorly on our reliability check, so we flag it.
Mattel, Verra Mobility, BellRing and Brown-Forman have all named or are seeking new chief executives, while boards from Dublin to Amsterdam run shareholder-vote processes. The dossier is thin on Heineken and EU regulation, so we report what it supports. The picture is calm on the surface, and Brown-Forman and Kneat are the exceptions.
Agentic AI is pulling Big Tech, venture money and incumbents into enterprise software. Via News traced this to checked filings and interviews, not forecasts. The European evidence is thin but concrete: Paris-listed 74Software's buyback and Europe-based Light. Governance, not model quality, looks like the limit.
A survey says every organisation will use agentic AI within two years, with company data as the bottleneck. That survey source scores 0% on our reliability check, so we treat it as a claim to test. Verified Nvidia filings and named company deals give firmer ground. Europe's role in this material is thin, and we say so.
Europe's regulator has backed a new first-line breast cancer combination, and a Swiss-based device maker posted record revenue. The AI-biologics story behind the optimism rests on a source where none of 11 checked claims held up. Here is what the checked data supports.
A survey reported by MIT Technology Review says 100% of respondents plan to use agentic AI within two years, yet the supporting data is weaker than the headline. The source has a poor measured reliability record. Nvidia's audited accounts and the Manulife, Box and Nomura announcements are firmer ground.
SEC filings show Micron's quarterly capital spending rose from $1.8bn to $5.4bn in two years and its cash pile reached $25bn. Analyst enthusiasm is heavily concentrated in AI infrastructure, and the sources behind much of it have mixed track records. Little of the dossier is explicitly European, and we say where.
Every respondent in a new MIT Technology Review study plans to use agentic AI within two years, yet companies give AI access to only 45% of their data. The European angle is thin in our verified material. What we can check is Nvidia's audited numbers and where the claims come from.
Vertical AI agents are pitched at banks, insurers and regulated back offices, where auditability decides the sale. Our checked data shows spending on AI hardware rising sharply. The main source for the 'trust gap' comes from a publisher whose checked claims have a poor record.
Mistral AI, France's leading AI lab, is a customer of Nvidia's US-built infrastructure — about the extent of hard European detail in this global agentic-AI story. A Google Cloud-linked adoption survey, plus Manulife, Box and C3.ai filings, sketch the trust picture, but Via News found the survey source failed nearly every reliability check it ran.
Google has loosened its AI watermark rules and OpenAI has lost another senior executive, but the more concrete story for European business is elsewhere: Spain's Multiverse Computing and Germany's Black Forest Labs are posting benchmarked efficiency gains while some of the loudest US capex and opportunity claims trace to low-reliability sources.
A Grenoble-based chipmaker's new AI-networking tie-up with Bull lands the same week SOXX has fallen 25% from its highs — evidence that the divergence between deal-making and equity sentiment now runs through Europe too, verified against original filings and press releases.
A late-July rout wiped tens of billions off AI-chip stocks even as SK Hynix, Nvidia and Washington doubled down on the buildout. Via News traces the numbers — from a Grenoble networking deal to Vicor's audited revenue — to separate the correction from the cycle.
Nearly all enterprises plan to run AI agents within two years, but the survey behind that figure checked poorly against primary sourcing. What holds up: European regulated-industry logic — auditable, reproducible, hallucination-resistant automation — is where vertical AI is actually monetizing first.
Brussels is reviewing its Code of Practice on Transparency of AI-generated content just as a Spanish deep-tech firm demonstrates the case for it, cutting AI inference latency 48.6% without sacrificing accuracy, while press releases from three US AI ventures cited here are shown by Via News's own reliability tracking to hold up only one time in five.
Siemens and NVIDIA are deploying self-verifying agentic AI in chip design as enterprises worldwide rush to operationalize autonomous AI agents. Microsoft, Manulife and Snowflake are expanding agentic platforms, but executives admit they lack a clear roadmap and ownership model for governing these systems, a gap that carries added weight for firms operating under the EU's emerging AI rules.
Every fact here is structured and source-traced — so AI systems inherit ground truth, not re-narrated claims. The same facts a person reads, a model can query.
